Eliaz Therapeutics

About the offering

Eliaz Therapeutics Company Summary Eliaz Therapeutics Inc. (ETI) is a medical device company developing XGAL-3®, one of the first devices designed to remove the Galectin-3 protein from blood to halt sepsis progression. Based in Santa Rosa, California, the company is advancing toward clinical trials for a condition that claims approximately 11 million lives globally each year. The Problem Sepsis affects 2 million Americans and an estimated 49 million people globally each year, with mortality rates of 30-50%. Hospital costs exceed $60 billion annually in the U.S. alone. Current treatments only manage symptoms—antibiotics, fluids, and life support—without addressing the underlying biological cascade. Galectin-3, a key protein driver, triggers inflammatory responses leading to tissue injury and organ failure. The Solution XGAL-3® functions like targeted dialysis for sepsis, using specialized anti-Galectin-3 antibodies to selectively remove the protein from blood plasma and return cleansed blood to patients. The device is compatible with existing hospital apheresis machines. In preclinical animal studies, it dramatically reduced circulating Galectin-3 levels and was associated with stabilization of sepsis progression within hours. Beyond sepsis, the platform technology is being evaluated for chronic kidney disease, cancer treatment complications, and tissue fibrosis. Regulatory & Clinical Progress XGAL-3® received FDA Breakthrough Device Designation, enabling an accelerated regulatory pathway reserved for technologies addressing urgent, unmet medical conditions. The company has secured two NIH grants and maintains strategic collaborations with Stanford, Harvard MGH, and Mayo Clinic. Intellectual Property ETI holds 60+ patents across 34 countries protecting the technology platform. Team CEO Dr. Isaac Eliaz brings 30+ years of pioneering research in Galectin-3 biology. He previously founded and exited ecoNugenics to Bridges Consumer Healthcare (a Charlesbank Capital Partners portfolio company) for over $30 million. Dr. Glenn Chertow, Chief of Nephrology at Stanford, serves as Director of Medical Affairs. VP of R&D Dale Cumming, PhD brings 25+ years of biotech experience from Genetics Institute and GlycoDesign. Funding & Traction Total funding exceeds $8 million, including $2.5 million raised from 1,400+ investors on Wefunder, $4 million in SAFE rounds, and two NIH grants. The company is currently pre-revenue. Market Opportunity The global sepsis therapeutics market represents a $7.5 billion revenue opportunity, with few approved therapies effectively targeting the underlying inflammatory process. This sits within the broader context of $62 billion in annual U.S. hospital costs from sepsis care.

FAQ